Zhang Yong-hai, Xie Dan, Luo Jun-hang, Chen Wei, Chen Ling-wu, Xu Qing-chun
Department of Urology, Shantou Central Hospital, Guangdong 515031, China.
Zhonghua Yi Xue Za Zhi. 2006 Sep 26;86(36):2556-9.
To investigate the amplification and expression of FGF3 in bladder transitional cell carcinoma (BTCC) and its clinical significance.
Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) methods were used to examine the protein expression and amplification of FGF3 in a tissue microarray (TMA) of 100 BTCCs and 30 adjacent normal bladder mucosas, so as to analyze their correlation and association with patient's clinico-pathological features.
In this study, none of the normal bladder mucosas were detected FGF3 positivity, while in 89 informative BTCCs, 20 (22%) cases were observed positive expression of FGF3 protein, and it was significantly more frequently to occur in BTCCs of poor-differentiation (Grade 3), later clinical stage (T2-4) and tumor in >or= 3 cm in diameter (P < 0.05). In FISH study, 10 of the 63 (16%) informative BTCCs were observed amplification of FGF3 and it was significantly associated with BTCC's tumor size and clinical stage (P < 0.05). In addition, 10 BTCCs with amplification of FGF3 in this study were all detected positive expression of FGF3 protein, while in the remaining 53 BTCCs without amplification of FGF3, only 3 (6%) cases were observed FGF3 protein positivity.
The up-regulated expression of FGF3 in BTCC was associated closely with tumor's malignant clinical phenotypes, and it might be involved in the malignant progression of parts of BTCC. The amplification of FGF3 gene might be a predominant mechanism of increased expression of FGF3 protein in BTCC.
探讨成纤维细胞生长因子3（FGF3）在膀胱移行细胞癌（BTCC）中的扩增及表达情况及其临床意义。
采用免疫组织化学（IHC）和荧光原位杂交（FISH）方法，检测100例BTCC组织芯片（TMA）及30例膀胱正常黏膜组织中FGF3的蛋白表达及扩增情况，分析其与患者临床病理特征的相关性。
本研究中，正常膀胱黏膜均未检测到FGF3阳性表达；而在89例有信息的BTCC中，20例（22%）观察到FGF3蛋白阳性表达，且在低分化（3级）、临床分期较晚（T2 - 4）及直径≥3 cm的BTCC中更易出现（P < 0.05）。FISH研究中，63例有信息的BTCC中有10例（16%）观察到FGF3扩增，且与BTCC的肿瘤大小及临床分期显著相关（P < 0.05）。此外，本研究中10例FGF3扩增的BTCC均检测到FGF3蛋白阳性表达，而在其余53例无FGF3扩增的BTCC中，仅3例（6%）观察到FGF3蛋白阳性。
BTCC中FGF3表达上调与肿瘤恶性临床表型密切相关，可能参与部分BTCC的恶性进展。FGF3基因扩增可能是BTCC中FGF3蛋白表达增加的主要机制。
